Azithromycin in Atopic Dermatitis

Evaluation of the Value of Adding Azithromycin to Topical Treatment in Mild to Moderate Atopic Dermatitis

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07713186

Enrollment

Registered

2026-07-20

Start date

2026-08-01

Completion date

2027-01-01

Last updated

2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Keywords

Atopic dermatitis, Azithromycin

Brief summary

The study will evaluate the role of adding azithromycin to topical treatment in patients with mild to moderate atopic dermatitis

Interventions

DRUGBetamethasone or tacrolimus ointments

Topical treatment will be applied, Betamethasone or tacrolimus ointments

DRUGAzithromycin

Azithromycin will be combined with topical treatment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

3 Years to 12 Years

Healthy volunteers

Inclusion criteria

* Both genders, ages from 3 to 12 years old with mild to moderate atopic dermatitis

Exclusion criteria

* Atopic dermatitis on active systemic treatment

Design outcomes

Primary

Measure	Time frame	Description
Improvement in Eczema Area and Severity Index (EASI)	3 months	The primary outcome will be the change in the Eczema Area and Severity Index (EASI) score from baseline to the end of the treatment period. The EASI is a validated clinician-assessed tool that evaluates the severity and extent of atopic dermatitis by assessing erythema, edema/papulation, excoriation, and lichenification across four body regions. Scores range from 0 to 72, with higher scores indicating more severe disease. Outcome variable: Mean change in EASI score from baseline. Assessment time points: Baseline, Week 2, Week 4, Week 8, and end of follow-up. Treatment response: Proportion of patients achieving EASI-50, EASI-75, and EASI-90 (≥50%, ≥75%, and ≥90% improvement from baseline).

Secondary

Measure	Time frame	Description
Investigator's Global Assessment (IGA)	4 months	The Investigator's Global Assessment will be used to evaluate the overall clinical severity of atopic dermatitis. Scale: 0 = Clear 1. = Almost clear 2. = Mild 3. = Moderate 4. = Severe Outcome variables: Mean change in IGA score. Percentage of patients achieving IGA 0/1 (clear or almost clear).
Pruritus Severity	3	Pruritus will be assessed using a 10-cm Visual Analog Scale (VAS) or Numeric Rating Scale (NRS, 0-10). 0 = No itch 10 = Worst imaginable itch Outcome: Mean reduction in pruritus score.

Countries

Egypt

Contacts

CONTACTAmira Elbendary, MD

aelbendary@kasralainy.edu.eg+201552208664

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 21, 2026